IBI343 not checked

Innovent

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .”In the company’s words, NCT06238843 on ClinicalTrials.gov
Tested for
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer, CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable or Metastatic Solid Tumors
Main trialPhase 3
“This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)”In the company’s words, NCT06238843 on ClinicalTrials.gov
Other names
Arcotatug Tavatecan

Other drugs for Pancreatic Cancer

All 203 drugs for Pancreatic Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Dec 2026 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
Phase 3Recruiting 30 Jun 2027 A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Phase 2Recruiting 31 Mar 2028 IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Phase 1Recruiting 30 Jun 2027 A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IBI343

Following is part of Solo: you see every change to IBI343 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in